NCT05382325View on ClinicalTrials.gov

A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 16, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Advanced or Metastatic Solid Tumors
Interventions
BIOLOGICAL

MK-1484

Subcutaneous (SC) injection

BIOLOGICAL

Pembrolizumab

Intravenous (IV) infusion

Trial Locations (8)

57104

Sanford Cancer Center ( Site 0005), Sioux Falls

78229

NEXT Oncology ( Site 0001), San Antonio

3109601

Rambam Health Care Campus-Oncology ( Site 0021), Haifa

5265601

Sheba Medical Center-ONCOLOGY ( Site 0020), Ramat Gan

M5G 2M9

Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0011), Toronto

1066CX

Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0035), Amsterdam

3015 GD

Erasmus Medisch Centrum-Medical Oncology ( Site 0036), Rotterdam

3584 CX

Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 0037), Utrecht

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY